The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Roche
Speakers' Bureau - MSD; Novartis
NRAS-mutated melanoma patients have similar response rates to therapy with checkpoint inhibitors as other cohorts.
 
Michael Constantin Kirchberger
Honoraria - Bristol-Myers Squibb
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Novartis
 
Selma Ugurel
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche
 
Joanna Mangana
Travel, Accommodations, Expenses - MSD
 
Markus Heppt
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Thomas Eigentler
No Relationships to Disclose
 
Carola Berking
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Roche
 
Dirk Schadendorf
Honoraria - Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech
 
Gerold Schuler
Stock and Other Ownership Interests - Argos Therapeutics
 
Reinhard Dummer
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda
Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda
 
Lucie Heinzerling
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche